236 related articles for article (PubMed ID: 15966562)
1. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
3. Hypercalcemia: an evidence-based approach to clinical cases.
Assadi F
Iran J Kidney Dis; 2009 Apr; 3(2):71-9. PubMed ID: 19395781
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis].
Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC
Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
7. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Intravenous Pamidronate for Parathyroid Hormone-dependent Hypercalcemia in Hospitalized Patients.
Rosenblum RC; Twito O; Barzilay-Yoseph L; Ramaty E; Klein N; Rotman-Pikielny P
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4593-e4602. PubMed ID: 34157125
[TBL] [Abstract][Full Text] [Related]
9. Hypercalcemia: A Review.
Walker MD; Shane E
JAMA; 2022 Oct; 328(16):1624-1636. PubMed ID: 36282253
[TBL] [Abstract][Full Text] [Related]
10. Medical treatment of malignancy-associated hypercalcemia.
Lumachi F; Brunello A; Roma A; Basso U
Curr Med Chem; 2008; 15(4):415-21. PubMed ID: 18288996
[TBL] [Abstract][Full Text] [Related]
11. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic hypercalcemia.
Camozzi V; Luisetto G; Basso SM; Cappelletti P; Tozzoli R; Lumachi F
Med Chem; 2012 Jul; 8(4):556-63. PubMed ID: 22571196
[TBL] [Abstract][Full Text] [Related]
13. A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
Kim S
J Oncol Pharm Pract; 2019 Oct; 25(7):1787-1793. PubMed ID: 30419769
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate nephrotoxicity.
Perazella MA; Markowitz GS
Kidney Int; 2008 Dec; 74(11):1385-93. PubMed ID: 18685574
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and therapy of hypercalcemia.
Khoury N; Carmichael KA
Mo Med; 2011; 108(2):99-103. PubMed ID: 21568230
[TBL] [Abstract][Full Text] [Related]
17. Modern management of malignant hypercalcemia.
Legrand SB
Am J Hosp Palliat Care; 2011 Nov; 28(7):515-7. PubMed ID: 21724679
[TBL] [Abstract][Full Text] [Related]
18. Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction.
Palmer S; Tillman F; Sharma P; Auten J; Owen K; Clark SM; Morgan KP
Ann Pharmacother; 2021 Mar; 55(3):303-310. PubMed ID: 32847379
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.
Hagelauer N; Pabst AM; Ziebart T; Ulbrich H; Walter C
Clin Oral Investig; 2015 Jan; 19(1):139-48. PubMed ID: 24668343
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
